Evidence map›Paper›PMID 39057558›Full record

ReviewHealthcare (Basel, Switzerland)2024

Post-Ischemic Stroke Cardiovascular Risk Prevention and Management.

Yilei Guo, Danping Pan, Haitong Wan, Jiehong Yang

Abstract readReview
In one paragraph

Review in Healthcare (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yilei GuoCollege of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID 0000-0003-2629-8581
Danping PanCollege of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Haitong WanThe First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou 310003, China.
Jiehong YangCollege of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.

Funding

National Key R&D Program of China No. 2023YFC3503100, 2023YFC3503103
6 · The paper itself

Abstract

Cardiac death is the second most common cause of death among patients with acute ischemic stroke (IS), following neurological death resulting directly from acute IS. Risk prediction models and screening tools including electrocardiograms can assess the risk of adverse cardiovascular events after IS. Prolonged heart rate monitoring and early anticoagulation therapy benefit patients with a higher risk of adverse events, especially stroke patients with atrial fibrillation. IS and cardiovascular diseases have similar risk factors which, if optimally managed, may reduce the incidence of recurrent stroke and other major cardiovascular adverse events. Comprehensive risk management emphasizes a healthy lifestyle and medication therapy, especially lipid-lowering, glucose-lowering, and blood pressure-lowering drugs. Although antiplatelet and anticoagulation therapy are preferred to prevent cardiovascular events after IS, a balance between preventing recurrent stroke and secondary bleeding should be maintained. Optimization of early rehabilitation care comprises continuous care across environments thus improving the prognosis of stroke survivors.

Indexed as

adverse cardiovascular eventscardiovascular diseaseischemic strokerisk management

Identifiers

PMID39057558
PMCPMC11276751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.